Dual Stimuli-Responsive Multifunctional Silicon Nanocarriers for Specifically Targeting Mitochondria in Human Cancer Cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Vy Anh Tran | - |
dc.contributor.author | Giau Van Vo | - |
dc.contributor.author | Tan, Mario A. | - |
dc.contributor.author | Park, Joon-Seo | - |
dc.contributor.author | An, Seong Soo A. | - |
dc.contributor.author | Lee, Sang-Wha | - |
dc.date.accessioned | 2022-05-13T07:40:07Z | - |
dc.date.available | 2022-05-13T07:40:07Z | - |
dc.date.created | 2022-05-12 | - |
dc.date.issued | 2022-04 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/84281 | - |
dc.description.abstract | Specific targeting, selective stimuli-responsiveness, and controlled release of anticancer agents are requested for high therapeutic efficiency with a minimal adverse effect. Herein, we report the sophisticated synthesis and functionalization of fluorescent mesoporous silicon (FMPSi) nanoparticles decorated with graphene oxide (GO) nanosheets. GO-wrapped FMPSi (FMPSi@GO) was loaded with a cisplatin (Cis) anticancer agent, and Cis-loaded FMPSi@GO (FMPSi-Cis@GO) exhibited the dual stimuli (pH and NIR)-responsiveness of controlled drug release, i.e., the drug release rate was distinctly enhanced at acidic pH 5.5 than at neutral pH 7.0 and further enhanced under NIR irradiation at acidic pH condition. Notably, dequalinium-conjugated FMPSi-Cis@GO (FMPSi-Cis@GO@DQA) demonstrated an excellent specificity for mitochondrial targeting in cancer cells without noticeable toxicity to normal human cells. Our novel silicon nanocarriers demonstrated not only stimuli (pH and NIR)-responsive controlled drug release, but also selective accumulation in the mitochondria of cancer cells and destroying them. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | PHARMACEUTICS | - |
dc.title | Dual Stimuli-Responsive Multifunctional Silicon Nanocarriers for Specifically Targeting Mitochondria in Human Cancer Cells | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000786980100001 | - |
dc.identifier.doi | 10.3390/pharmaceutics14040858 | - |
dc.identifier.bibliographicCitation | PHARMACEUTICS, v.14, no.4 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85129212934 | - |
dc.citation.title | PHARMACEUTICS | - |
dc.citation.volume | 14 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Vy Anh Tran | - |
dc.contributor.affiliatedAuthor | An, Seong Soo A. | - |
dc.contributor.affiliatedAuthor | Lee, Sang-Wha | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | mesoporous silicon | - |
dc.subject.keywordAuthor | controlled drug release | - |
dc.subject.keywordAuthor | graphene oxide | - |
dc.subject.keywordAuthor | dequalinium | - |
dc.subject.keywordAuthor | mitochondria targeting | - |
dc.subject.keywordPlus | PHYSICAL ADSORPTION CHARACTERIZATION | - |
dc.subject.keywordPlus | GRAPHENE OXIDE | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordPlus | POROUS SILICON | - |
dc.subject.keywordPlus | NANOPARTICLES | - |
dc.subject.keywordPlus | RELEASE | - |
dc.subject.keywordPlus | NANOCOMPOSITES | - |
dc.subject.keywordPlus | DEGRADATION | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | SIMULATION | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.